Skip to main content
Edgewise Therapeutics, Inc. logo

Edgewise Therapeutics, Inc. — Investor Relations & Filings

Ticker · EWTX ISIN · US28036F1057 US Manufacturing
Open in API
Filings indexed 372 across all filing types
Latest filing 2022-09-16 Major Shareholding Noti…
Country US United States of America
Listing US EWTX

About Edgewise Therapeutics, Inc.

https://edgewisetx.com/

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for severe and rare muscle disorders. The company leverages its expertise in muscle science to create precision medicines for conditions including muscular dystrophies and serious cardiac diseases. Its primary goal is to develop treatments that address the underlying causes of these debilitating conditions to improve the lives of patients and their families.

Recent filings

Filing Released Lang Actions
SC 13D/A
Major Shareholding Notification
2022-09-16 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 13, 2022, by Edgewise Therapeutics, Inc. It reports the entry into a material definitive agreement, specifically an underwriting agreement related to a public offering of common stock. The document details the terms of the offering, the parties involved, and includes exhibits such as the underwriting agreement and legal opinion. There are no financial statements or comprehensive financial data presented, nor is this a full annual or quarterly report. The content focuses on a capital raising event and financing activity. Therefore, this filing is best classified as a Capital/Financing Update (CAP). The document length (6067 characters) and detailed description of the underwriting agreement support this classification with high confidence.
2022-09-14 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common stock by Edgewise Therapeutics, Inc. It includes detailed information about the offering terms, underwriting, risk factors, use of proceeds, and legal matters. The document is a registration statement supplement and prospectus, which is a type of capital raising disclosure. It is not an annual report, earnings release, or management discussion. It is not a report of voting results, nor a board or management change announcement. It is not a transcript or audit report. The document is clearly related to a financing event, specifically a public offering of shares. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, supporting a high confidence in this classification.
2022-09-14 English
424B5
Capital/Financing Update Classification · 100% confidence The document is titled as a "Prospectus supplement" and includes detailed sections such as "The offering," "Use of proceeds," "Dividend policy," "Underwriting," and legal matters. It references a registration statement on Form S-3 filed with the SEC and discusses the offering of common stock. This type of document is a detailed disclosure related to a securities offering, typically used to inform investors about the terms and risks of the offering. It is not a financial report, earnings release, or management discussion, but rather a capital markets document related to financing activities. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is the actual prospectus supplement, not just an announcement of it, so it is not RPA or RNS.
2022-09-13 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes of importance to shareholders. The text includes announcements of FDA authorization for a clinical trial, interim study results, and updated risk factor disclosures referencing a prior 10-Q filing. It does not contain comprehensive financial statements or detailed financial analysis itself, but rather updates and press releases incorporated by reference. The document length is 4568 characters, which is relatively short and consistent with a current report rather than a full financial report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories like Annual Report or Interim Report.
2022-09-13 English
PRIMARY DOCUMENT
Director's Dealing
2022-09-08 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.